By Sabela Ojea

 

AstraZeneca PLC said Wednesday that its Tagrisso medicine has been approved in China for the treatment of early lung cancer.

The U.K.-based pharmaceutical giant said Tagrisso is the first such drug to have received approval in China, as well as the only one to have shown efficacy against the disease in a global trial.

The FTSE 100 company added that the approval is based on the positive results coming from the Adaura Phase 3 trial, where Tagrisso was proven to reduce the risk of disease recurrence or death by 80%.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

April 14, 2021 02:33 ET (06:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.